The Ultimaster coronary stent system: 5-year worldwide experience.
Elisa GherbesiGian Battista DanziPublished in: Future cardiology (2020)
Newer generation drug-eluting stents have significantly improved outcomes in patients undergoing percutaneous coronary intervention by reducing the risk of restenosis and stent thrombosis. In comparison with first-generation ones, contemporary drug-eluting stents have thinner struts and more biocompatible polymers, which reduce inflammation, promote endothelialization and decrease neointimal proliferation. The Ultimaster™/Ultimaster™ Tansei™ coronary stent system is a cobalt-chromium, biodegradable polymer, sirolimus-eluting stent (Terumo, Tokyo, Japan) that received the Conformitè Européenne mark approval for clinical use in 2014/2018. This device has been the object of intense clinical evaluation in controlled randomized studies and observational registries. In this article, we analytically reviewed the available clinical data with a focus on the latest real-world evidence that demonstrates excellent performance in all of the clinical subsets.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- clinical evaluation
- patients undergoing
- coronary artery
- acute coronary syndrome
- type diabetes
- open label
- drug delivery
- signaling pathway
- emergency department
- metabolic syndrome
- st segment elevation myocardial infarction
- ionic liquid
- gold nanoparticles
- deep learning
- electronic health record
- smooth muscle
- transcatheter aortic valve replacement
- insulin resistance
- artificial intelligence
- aortic stenosis